Best Supplements for Inflammation
"Inflammaging" — chronic low-grade inflammation — predicts cardiovascular and metabolic disease and accelerates every other hallmark. These compounds have human evidence for lowering inflammatory markers (hs-CRP, IL-6) through NRF2, SPM resolution, and NF-κB pathways.
Ranked by strength of human evidence (Tier A > B > C) and mechanistic fit — computed from the compound registry, not hand-picked. Every entry links to its full evidence deep-dive with PubMed citations. Educational only, not medical advice.
- 1
Omega-3 (EPA + DHA)
Tier ASpecialized Pro-resolving Mediators (SPMs) — Tier A.
2–4g combined EPA+DHA daily (with fat-containing meals)·AM/PM·3 PMIDs - 2
Trans-Resveratrol
Tier BSirtuin Activation — Tier B.
150–500mg trans-resveratrol·PM·3 PMIDs - 3
GlyNAC
Tier AGlutathione Synthesis — Tier A.
600mg glycine + 600mg NAC·AM·2 PMIDs - 4
Curcumin (Curcuminoids)
Tier BNF-κB Suppression / Nrf2 Activation — Tier B.
1,000–1,500mg/day curcuminoids (enhanced-bioavailability form, split AM/PM with fat)·AM/PM·3 PMIDs - 5
Sulforaphane
Tier ANRF2 Activation — Tier A.
10–35mg glucoraphanin·AM·2 PMIDs - 6
Fisetin
Tier BSenolytic Clearance — Tier B.
100–500mg fisetin (pulse: 2 consecutive days per month preferred)·AM·1 PMID - 7
NMN
Tier ANAD+ Restoration — Tier A.
250–500mg NMN·AM·3 PMIDs - 8
Quercetin
Tier BSenolysis via SCAP Inhibition — Tier B.
500mg/day (bioavailability-enhanced form); D+Q senolytic use is physician-supervised only·AM·3 PMIDs
The aging mechanisms behind this goal
Want a stack built for you, not a list?
The NICO Starter Questionnaire turns your goals, lifestyle, and safety profile into a personalized, evidence-graded stack — and loads it straight into Stack Builder.
Take the NICO Starter QuestionnaireFrequently asked
What supplement lowers hs-CRP the most?
Omega-3 (EPA+DHA) has the largest cardiovascular evidence base and reliably lowers hs-CRP and IL-6, with the REDUCE-IT trial showing a 25% reduction in major cardiovascular events at 4g/day EPA. Sulforaphane and GlyNAC also reduce inflammatory markers in human trials.